According to a new study published in JAMA, giving a subcutaneous antibody combination of casirivimab and imdevimab to asymptomatic individuals who have tested positive for SARS-CoV-2 can significantly reduce the incidence of symptomatic COVID-19 over 28 days.

The study included 314 participants, of whom 310 (99.7%) completed the efficacy assessment period. Overall, 204 were asymptomatic and tested seronegative at baseline and were included in the primary efficacy analysis. The administration of subcutaneous combination of casirivimab and imdevimab 1200 mg (600 mg each) significantly prevented progression to symptomatic illness (29.0% vs. 42.3% with placebo).

The findings point to a new potential for monoclonal antibody treatment, which is currently being used for postexposure prophylaxis and treatment of symptomatic COVID-19 infection… (Medscape)